FGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2022 Jun 17

PMID 35712652

Authors

Chen Hong

Jianping Wei

Tao Zhou

Xia Wang

Jing Cai

Affiliations

Soon will be listed here.

Abstract

Background: Fibroblast growth factor receptor (FGFR) fusions in non-small cell lung cancer (NSCLC) are small genomic events. At present, there is no standard treatment strategy for patients with NSCLC carrying an FGFR fusion.

Case Presentation: We report the case of a 45-year-old female patient who was diagnosed with lung adenocarcinoma and underwent right upper lobectomy and postoperative adjuvant chemotherapy. After 13 months, the patient's lung lesions progressed. Next-generation sequencing of venous blood and lung tissues confirmed an FGFR2-ERC1 fusion, and she received chemotherapy and immunotherapy. Two months later, the patient's lung lesions progressed again. Based on the target effect of anlotinib on FGFR, the patient was subsequently treated with anlotinib, and the progression-free survival interval exceeded 8.0 months.

Conclusion: These findings showed that patients with lung adenocarcinoma carrying an FGFR2-ERC1 fusion gene may benefit from anlotinib. This case provided evidence to support the use of anlotinib in the treatment of NSCLC patients with FGFR fusion gene subtypes.

Citing Articles

Activation of FGFR genes by genetic and epigenetic alterations in uterine leiomyomas.

Jokinen V, Taira A, Kolterud A, Ahlgren I, Palin K, Katainen R BJC Rep. 2025; 3(1):9.

PMID: 40016412 PMC: 11868550. DOI: 10.1038/s44276-025-00127-4.

[Aumolertinib combined with anlotinib inhibits proliferation of non-small cell lung cancer cells by down-regulating the PI3K/AKT pathway].

Yang Y, Liu X, Liu W, Zhou X, Zhang Z, Hu Y Nan Fang Yi Ke Da Xue Xue Bao. 2024; 44(10):1965-1975.

PMID: 39523097 PMC: 11526449. DOI: 10.12122/j.issn.1673-4254.2024.10.15.

Case report: a case of lung squamous cell carcinoma with a novel FGFR3-IER5L fusion mutation responding to anlotinib.

Chen X, Zhao W, Yu H, Wang S, Wang C, Song Y Front Oncol. 2024; 14:1391349.

PMID: 39421453 PMC: 11484447. DOI: 10.3389/fonc.2024.1391349.

References

Shao L, Wang W, Song Z, Zhang Y . The efficacy and safety of anlotinib treatment for advanced lung cancer. Onco Targets Ther. 2019; 12:6549-6554. PMC: 6699585. DOI: 10.2147/OTT.S205674. View

Scheiter A, Keil F, Luke F, Grosse J, Verloh N, Opitz S . Identification and In-Depth Analysis of the Novel FGFR2-NDC80 Fusion in a Cholangiocarcinoma Patient: Implication for Therapy. Curr Oncol. 2021; 28(2):1161-1169. PMC: 8025813. DOI: 10.3390/curroncol28020112. View

Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre M . The Global Burden of Cancer 2013. JAMA Oncol. 2015; 1(4):505-27. PMC: 4500822. DOI: 10.1001/jamaoncol.2015.0735. View

Gu W, Yang J, Wang Y, Xu J, Wang X, Du F . Comprehensive identification of alterations in 5 557 Chinese patients with solid tumors by next-generation sequencing. Am J Cancer Res. 2021; 11(8):3893-3906. PMC: 8414391. View

Ma J, Wang B, Meng E, Meng X . Case report: identification of fusion in a patient with pancreatic ductal adenocarcinoma. Gland Surg. 2021; 10(9):2874-2879. PMC: 8514310. DOI: 10.21037/gs-21-469. View

Katoh M, Nakagama H . FGF receptors: cancer biology and therapeutics. Med Res Rev. 2013; 34(2):280-300. DOI: 10.1002/med.21288. View

Williams S, Hurst C, Knowles M . Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet. 2012; 22(4):795-803. PMC: 3554204. DOI: 10.1093/hmg/dds486. View

Touat M, Ileana E, Postel-Vinay S, Andre F, Soria J . Targeting FGFR Signaling in Cancer. Clin Cancer Res. 2015; 21(12):2684-94. DOI: 10.1158/1078-0432.CCR-14-2329. View

Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z . Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018; 11(1):120. PMC: 6146601. DOI: 10.1186/s13045-018-0664-7. View

10.

Wang H, Chu J, Zhao Y, Tang H, Wang L, Zhou M . A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer. Cancer Manag Res. 2020; 12:3827-3834. PMC: 7250176. DOI: 10.2147/CMAR.S249678. View

11.

Lowery M, Ptashkin R, Jordan E, Berger M, Zehir A, Capanu M . Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. Clin Cancer Res. 2018; 24(17):4154-4161. PMC: 6642361. DOI: 10.1158/1078-0432.CCR-18-0078. View

12.

Shi M, Wang W, Zhang J, Li B, Lv D, Wang D . Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing. Cancer Sci. 2021; 113(1):308-318. PMC: 8748217. DOI: 10.1111/cas.15181. View

13.

Singh D, Chan J, Zoppoli P, Niola F, Sullivan R, Castano A . Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012; 337(6099):1231-5. PMC: 3677224. DOI: 10.1126/science.1220834. View

14.

Wesche J, Haglund K, Haugsten E . Fibroblast growth factors and their receptors in cancer. Biochem J. 2011; 437(2):199-213. DOI: 10.1042/BJ20101603. View

15.

Hubbard S, Till J . Protein tyrosine kinase structure and function. Annu Rev Biochem. 2000; 69:373-98. DOI: 10.1146/annurev.biochem.69.1.373. View

16.

De Luca A, Esposito Abate R, Rachiglio A, Maiello M, Esposito C, Schettino C . FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention. Int J Mol Sci. 2020; 21(18). PMC: 7555921. DOI: 10.3390/ijms21186856. View

17.

Babina I, Turner N . Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017; 17(5):318-332. DOI: 10.1038/nrc.2017.8. View

18.

Roskoski Jr R . The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharmacol Res. 2019; 151:104567. DOI: 10.1016/j.phrs.2019.104567. View

19.

Xiong Q, Qin B, Xin L, Yang B, Song Q, Wang Y . Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer. Front Oncol. 2021; 11:659380. PMC: 8358741. DOI: 10.3389/fonc.2021.659380. View

20.

Zhang L, Lu J, Liu R, Hu M, Zhao Y, Tan S . Chromatin accessibility analysis reveals that TFAP2A promotes angiogenesis in acquired resistance to anlotinib in lung cancer cells. Acta Pharmacol Sin. 2020; 41(10):1357-1365. PMC: 7608858. DOI: 10.1038/s41401-020-0421-7. View